Paul Wotton

Dr. Wotton previously served as the Founding Chief Executive Officer of Sigilon Therapeutics. Prior to Sigilon, Dr. Wotton served as President and Chief Executive Officer of Ocata Therapeutics until its acquisition by Astellas Pharma where he was also Co-Chairman of the Office of Integration. He has also served as President and Chief Executive Officer of Antares Pharma as well as Chief Executive Officer of Topigen Pharmaceuticals. Dr. Wotton has held senior leadership roles at SkyePharma, Eurand International, Penwest Pharmaceuticals, Abbott Laboratories as well as Merck and Sharp & Dohme (Merck & Co.). Dr. Wotton obtained his B.Pharm (Hons) from the University of London, holds his MBA from Kingston Business School, and received his Ph.D. from the University of Nottingham.